1. Final results of a phase I intermittent dose-escalation trial of ZD1839 (‘Iressa’) in Japanese patients with various solid tumors;Negoro;Proc Am Soc Clin Oncol,2001
2. Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices;Kameyama;Toxicol Lett,1990
3. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor (EGFR);Saltz;Proc Am Soc Clin Oncol,2002
4. A phase III clinical trial of ZD1839 (‘Iressa’) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1;Giaccone;Ann Oncol,2002
5. ZD1839 (“Iressa”) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2;Johnson;Ann Oncol,2002